{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:05:27Z","timestamp":1793675127323,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Chronic graft versus host disease is a major consequence after allogeneic stem cell transplantation (allo-SCT) and has great impact on patients\u2019 morbidity and mortality. Besides the skin, liver, and intestines, the eyes are most commonly affected, manifesting as severe ocular surface disease. Treatment protocols include topical steroids, cyclosporine, tacrolimus, and ASED. Since these patients often receive systemic immunosuppressant therapy from their oncologists, a topical re-administration of these drugs via ASED with potentially beneficial or harmful effects is possible. The purpose of the study was to determine whether and to which extent systemic immunosuppressants are detectable in ASED.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 34 samples of ASED from 16 patients with hemato-oncological malignancies after allo-SCT were collected during the manufacturing process and screened for levels of cyclosporine, mycophenolic acid, everolimus, and tacrolimus via liquid chromatography coupled with tandem mass spectrometry (LC-MS\/MS). The study followed the tenets of the Declaration of Helsinki and informed consent was obtained from the subjects after explanation of the nature and possible consequences of the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cyclosporine was found in 18 ASED samples in concentrations ranging from 6.5\u2013105.0\u00a0ng\/ml (32.0\u2009\u00b1\u200922.8\u00a0ng\/ml, mean \u00b1 SD). The concentration range of mycophenolic acid in 19 samples was 0.04\u201325.0\u00a0mg\/l (4.0\u2009\u00b1\u20095.4\u00a0mg\/l, mean \u00b1 SD). Everolimus and tacrolimus concentrations were well below the respective limits of quantification (&lt;\u20090.6 and &lt;\u20090.5\u00a0ng\/ml) of the established LC-MS\/MS method in all samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study suggests that orally administered cyclosporine and mycophenolic acid for the treatment of systemic GvHD, but not everolimus and tacrolimus, are distinctly detectable in ASED in relevant concentrations. It is highly likely that these agents affect topical therapy of ocular GvHD. However, the extent of this effect needs to be evaluated in further studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-020-04865-8","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T01:02:35Z","timestamp":1597798955000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Detection of systemic immunosuppressants in autologous serum eye drops (ASED) in patients with severe chronic ocular graft versus host disease"],"prefix":"10.1007","volume":"259","author":[{"given":"Volkan","family":"Tahmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H. J.","family":"Wiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Gehlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sauerbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Gathof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"4865_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2005.02.006","volume":"5","author":"Y Ichiki","year":"2006","unstructured":"Ichiki Y, Bowlus CL, Shimoda S et al (2006) T cell immunity and graft-versus-host disease (GVHD). Autoimmun Rev 5:1\u20139","journal-title":"Autoimmun Rev"},{"issue":"1","key":"4865_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.iac.2009.10.001","volume":"30","author":"SW Choi","year":"2010","unstructured":"Choi SW, Levine JE, Ferrara JLM (2010) Pathogenesis and management of graft versus host disease. Immunol Allergy Clin N Am 30(1):75\u2013101","journal-title":"Immunol Allergy Clin N Am"},{"key":"4865_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12185-015-1785-1","volume":"101","author":"MO Jamil","year":"2015","unstructured":"Jamil MO, Mineishi S (2015) State-of-the-art acute and chronic GVHD treatment. Int J Hematol 101:452\u2013466","journal-title":"Int J Hematol"},{"issue":"2","key":"4865_CR4","first-page":"251","volume":"21","author":"AH Filipovich","year":"2008","unstructured":"Filipovich AH (2008) Diagnosis and manifestations of chronic graft-versus-host disease. Clin Haematol 21(2):251\u2013257","journal-title":"Clin Haematol"},{"key":"4865_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1055\/s-0035-1545836","volume":"232","author":"T Dietrich-Ntoukas","year":"2015","unstructured":"Dietrich-Ntoukas T (2015) Clinical signs of ocular graft-versus-host disease. Klin Monatsbl Augenheilkd 232:647\u2013651","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"4865_CR6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/bmt.2015.72","volume":"50","author":"L Engel","year":"2015","unstructured":"Engel L, Wittig S, Bock F et al (2015) Meibography and meibomian gland measurements in ocular graft-versus-host disease. Bone Marrow Transplant 50:961\u2013967","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4865_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/bjo.77.8.525","volume":"77","author":"JD Heath","year":"1993","unstructured":"Heath JD, Acheson JF, Schulenburg WE (1993) Penetrating keratoplasty in severe ocular graft versus host disease. Br J Ophthalmol 77(8):525\u2013526","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"4865_CR8","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.ophtha.2016.02.044","volume":"123","author":"TB Abud","year":"2016","unstructured":"Abud TB, Amparo F, Saboo US et al (2016) A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease. Ophthalmology 123(7):1449\u20131457","journal-title":"Ophthalmology"},{"key":"4865_CR9","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.bbmt.2015.07.013","volume":"21","author":"Y Inamoto","year":"2015","unstructured":"Inamoto Y, Sun YC, Flowers MED et al (2015) Bandage soft contact lenses for ocular graft-versus-host disease. Biol Blood Marrow Transplant 21:2002\u20132007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"4865_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/jop.2012.0002","volume":"28","author":"KS Na","year":"2012","unstructured":"Na KS, Kim MS (2012) Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther 28(5):479\u2013483","journal-title":"J Ocul Pharmacol Ther"},{"issue":"33","key":"4865_CR11","first-page":"1","volume":"5","author":"VJ Drew","year":"2018","unstructured":"Drew VJ, Tseng CL, Seghatchian J et al (2018) Reflections on dry eye syndrome treatment: therapeutic role of blood products. Front Med 5(33):1\u201311","journal-title":"Front Med"},{"issue":"7","key":"4865_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/sj.bmt.1703862","volume":"31","author":"Y Ogawa","year":"2003","unstructured":"Ogawa Y, Okamoto S, Mori T et al (2003) Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 31(7):579\u2013583","journal-title":"Bone Marrow Transplant"},{"key":"4865_CR13","first-page":"322","volume":"101","author":"V Tahmaz","year":"2017","unstructured":"Tahmaz V, Gehlsen U, Sauerbier L et al (2017) Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. Br J Ophthalmol 101:322\u2013326","journal-title":"Br J Ophthalmol"},{"key":"4865_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.chroma.2012.04.008","volume":"1241","author":"M Wiesen","year":"2012","unstructured":"Wiesen M, Farowski F, Feldk\u00f6tter M et al (2012) Liquid chromatography-tandem mass spectrometry method for the quantification of mycophenolic acid and its penolic glucuronide in saliva and plasma using a standardized saliva collection device. J Chromatogr 1241:52\u201359","journal-title":"J Chromatogr"},{"key":"4865_CR15","first-page":"1436","volume":"31","author":"JG Walt","year":"1997","unstructured":"Walt JG, Rowe MM, Stern KL (1997) Evaluating the functional impact of dry eye: the ocular surface disease index. Drug Inf J 31:1436","journal-title":"Drug Inf J"},{"key":"4865_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-0033-1357976","volume":"4","author":"V Petrescu","year":"2014","unstructured":"Petrescu V, Radojska S, Tahmaz V et al (2014) Characteristics in manufacturing autologous serum eye drops. Transfusionsmedizin 4:139\u2013142","journal-title":"Transfusionsmedizin"},{"key":"4865_CR17","doi-asserted-by":"crossref","unstructured":"Geerling G, Hartwig D (2006) Autologous serum eye drops for ocular surface disorders. Cornea and external eye disease 1\u201320","DOI":"10.1007\/3-540-31226-9_1"},{"key":"4865_CR18","doi-asserted-by":"crossref","unstructured":"Tahmaz V, Radojska S, Cursiefen C et al (2017) Autologe Serumaugentropfen \u2013 Indikation, Herstellung, Anwendung. Augenheilkunde up2date;6:1\u20135","DOI":"10.1055\/s-0042-123226"},{"issue":"34","key":"4865_CR19","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","volume":"25","author":"E Robenshtok","year":"2007","unstructured":"Robenshtok E, Gafter-Gvili A, Goldberg E et al (2007) Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25(34):5471\u20135489","journal-title":"J Clin Oncol"},{"key":"4865_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","volume":"99","author":"P Reusser","year":"2002","unstructured":"Reusser P, Einsele H, Lee J et al (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99:1159\u20131164","journal-title":"Blood"},{"issue":"6","key":"4865_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/00007691-199412000-00012","volume":"16","author":"LJ Langman","year":"1994","unstructured":"Langman LJ, LeGatt DF, Yatscoff RW (1994) Blood distribution of mycophenolic acid. Ther Drug Monit 16(6):602\u2013607","journal-title":"Ther Drug Monit"},{"key":"4865_CR22","volume-title":"Personalized immunosuppression in transplantation: role of biomarker monitoring and therapeutic drug monitoring","author":"M Oellerich","year":"2016","unstructured":"Oellerich M, Dasgupta A (2016) Personalized immunosuppression in transplantation: role of biomarker monitoring and therapeutic drug monitoring. Elsevier, Amsterdam"},{"issue":"6","key":"4865_CR23","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/0190-9622(90)70354-K","volume":"23","author":"G Mockli","year":"1990","unstructured":"Mockli G, Kabra PM, Kurtz TW (1990) Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist. J Am Acad Dermatol 23(6):1275\u20131279","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"4865_CR24","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/clinchem\/40.12.2247","volume":"40","author":"M Winkler","year":"1994","unstructured":"Winkler M, Ringe B, Baumann J et al (1994) Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression. Clin Chem 40(12):2247\u20132253","journal-title":"Clin Chem"},{"issue":"2","key":"4865_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","volume":"43","author":"G Kirchner","year":"2004","unstructured":"Kirchner G, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43(2):83\u201395","journal-title":"Clin Pharmacokinet"},{"key":"4865_CR26","volume-title":"Therapeutic drug monitoring \u2013 newer drugs and biomarkers","author":"A Dasgupta","year":"2012","unstructured":"Dasgupta A (2012) Therapeutic drug monitoring \u2013 newer drugs and biomarkers. Academic Press, Cambridge"},{"issue":"1","key":"4865_CR27","first-page":"136","volume":"75","author":"J Andersson","year":"1992","unstructured":"Andersson J, Nagy S, Growth CG et al (1992) Effects of FK 506 and cyclosporin A on cytokine production studied in vitro at single-cell level. Immunology 75(1):136\u2013142","journal-title":"Immunology"},{"key":"4865_CR28","doi-asserted-by":"crossref","unstructured":"Fernandes-Ramos AA, Machetti-Laurent C, Poindessous V et al (2017) A comprehensive characterization of the impact of mycophenolic acid on the metabolism of Jurkat T cells. Sci Rep 7 Article number: 10550","DOI":"10.1038\/s41598-017-10338-6"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-04865-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T23:35:10Z","timestamp":1629329710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-04865-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4865"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04865-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"assertion":[{"value":"30 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University Hospital Cologne and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}